|
1) Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-13
|
|
|
|
2) Ueno H, Okusaka T, Ikeda M, et al. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005; 68: 171-8
|
|
|
|
|
3) Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol, in press
|
|
|
|
|
|
4) Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20: 3270-5
|
|
|
|
|
|
5) Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2005; 23: 16s
|
|
|
|
|
|
6) Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell' Italia Meridionale. Cancer. 2002; 94: 902-10
|
|
|
|
|
|
7) Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-52
|
|
|
|
|
|
8) Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: result of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 3509-16
|
|
|
|
|
|
9) Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22: 3776-83
|
|
|
|
|
|
10) Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006; 24: 4441-7
|
|
|
|
|
|
11) Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87: 161-7
|
|
|
|
|
|
12) Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22: 1430-8
|
|
|
|
|
|
13) Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005; 16: 1639-45
|
|
|
|
|
|
14) Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 2212-7
|
|
|
|
|
|
15) Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer. 2005; 2: 4 (suppl 3, abstr PS11)
|
|
|
|
|
|
16) Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6
|
|
|
|
|
|
17) Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc Am Soc Clin Oncol. 2007; 25: 18S
|
|
|
|
|
|
18) Ueno H, Okusaka T, Ikeda M, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005; 69: 421-7
|
|
|
|
|
|
19) Nakamura K, Yamaguchi T, Ishihara T, et al. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2005; 92: 2134-9
|
|
|
|
|
|
20) Rauchwerger DR, Firby PS, Hedley DW, et al. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000; 60: 6075-9
|
|
|
|
|
|
21) Ueno H, Okusaka T, Furuse J, et al. A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 2007; 25: 18S
|
|
|
|
|
|
22) Nakamura K, Yamaguchi T, Ishihara T, et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006; 94: 1575-9
|
|
|
|
|